藏而不露：治疗重症 COVID-19 感染患者的方法。
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
机构信息
57, chemin du Lavoir, Sergy Haut, France
Department of Medicine, Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA.
出版信息
mBio. 2020 Mar 20;11(2):e00398-20. doi: 10.1128/mBio.00398-20.
Abstract
Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.
摘要
感染 COVID-19 的患者有患急性呼吸窘迫综合征（ARDS）和死亡的风险。COVID-19 的组织受体是 ACE2，ACE2 水平较高可以预防 ARDS。血管紧张素受体阻滞剂和他汀类药物可上调 ACE2。需要临床试验来确定这种药物组合是否可用于治疗重症 COVID-19 感染患者。
相似文献
1
Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection.
mBio. 2020 Mar 20;11(2):e00398-20. doi: 10.1128/mBio.00398-20.
2
SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.
Theranostics. 2020 Jun 12;10(16):7448-7464. doi: 10.7150/thno.48076. eCollection 2020.
3
Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers.
Hypertension. 2020 Jun;75(6):1382-1385. doi: 10.1161/HYPERTENSIONAHA.120.15082. Epub 2020 Mar 25.
4
Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2.
J Endocrinol. 2020 Nov;247(2):R45-R62. doi: 10.1530/JOE-20-0260.
5
A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.
Elife. 2020 Jul 7;9:e59177. doi: 10.7554/eLife.59177.
6
Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.
Eur J Pharmacol. 2020 Oct 5;884:173455. doi: 10.1016/j.ejphar.2020.173455. Epub 2020 Jul 31.
7
Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19).
J Pathol. 2020 Jul;251(3):228-248. doi: 10.1002/path.5471. Epub 2020 Jun 10.
8
COVID-19 and Cardiovascular Disease.
Circulation. 2020 May 19;141(20):1648-1655. doi: 10.1161/CIRCULATIONAHA.120.046941. Epub 2020 Mar 21.
9
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin-angiotensin system.
Eur Heart J Cardiovasc Pharmacother. 2020 Sep 1;6(5):317-325. doi: 10.1093/ehjcvp/pvaa053.
10
Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2.
Circ Res. 2020 May 8;126(10):1456-1474. doi: 10.1161/CIRCRESAHA.120.317015. Epub 2020 Apr 8.
引用本文的文献
1
Bridging the gap between CVD and COVID-19: the oxidized LDL hypothesis.
Front Med (Lausanne). 2025 Aug 6;12:1588062. doi: 10.3389/fmed.2025.1588062. eCollection 2025.
2
Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial.
Sci Rep. 2024 Oct 23;14(1):25028. doi: 10.1038/s41598-024-72449-1.
3
Effect of polyphenols against complications of COVID-19: current evidence and potential efficacy.
Pharmacol Rep. 2024 Apr;76(2):307-327. doi: 10.1007/s43440-024-00585-6. Epub 2024 Mar 18.
4
Impact of in-hospital statin use on mortality in COVID-19 patients from a majority African American population.
Heart Lung. 2024 Mar-Apr;64:137-141. doi: 10.1016/j.hrtlng.2023.03.005. Epub 2023 Mar 13.
5
Target-agnostic drug prediction integrated with medical record analysis uncovers differential associations of statins with increased survival in COVID-19 patients.
PLoS Comput Biol. 2023 May 5;19(5):e1011050. doi: 10.1371/journal.pcbi.1011050. eCollection 2023 May.
6
Treating COVID-19: Targeting the Host Response, Not the Virus.
Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.
7
Multi-omics analysis reveals underlying host responses in pediatric respiratory syncytial virus pneumonia.
iScience. 2023 Mar 3;26(4):106329. doi: 10.1016/j.isci.2023.106329. eCollection 2023 Apr 21.
8
Phenotypical and Functional Alteration of γδ T Lymphocytes in COVID-19 Patients: Reversal by Statins.
Cells. 2022 Oct 31;11(21):3449. doi: 10.3390/cells11213449.
9
The Influence of SARS-CoV-2 Infection on Lipid Metabolism-The Potential Use of Lipid-Lowering Agents in COVID-19 Management.
Biomedicines. 2022 Sep 18;10(9):2320. doi: 10.3390/biomedicines10092320.
10
Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: a randomised clinical trial (RESIST trial).
BMC Infect Dis. 2022 Jul 9;22(1):606. doi: 10.1186/s12879-022-07570-5.
本文引用的文献
1
The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) - China, 2020.
China CDC Wkly. 2020 Feb 21;2(8):113-122.
2
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585.
3
Emerging coronaviruses: Genome structure, replication, and pathogenesis.
J Med Virol. 2020 Apr;92(4):418-423. doi: 10.1002/jmv.25681. Epub 2020 Feb 7.
4
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics.
N Engl J Med. 2019 Dec 12;381(24):2293-2303. doi: 10.1056/NEJMoa1910993. Epub 2019 Nov 27.
5
Treating Ebola in eastern DRC.
Lancet Infect Dis. 2019 Oct;19(10):1059-1060. doi: 10.1016/S1473-3099(19)30484-0.
6
The Damage-Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases.
J Infect Dis. 2018 Aug 14;218(suppl_1):S7-S11. doi: 10.1093/infdis/jiy083.
7
Clinician-initiated research on treating the host response to pandemic influenza.
Hum Vaccin Immunother. 2018 Mar 4;14(3):790-795. doi: 10.1080/21645515.2017.1378292. Epub 2017 Oct 31.
8
Treating the host response to emerging virus diseases: lessons learned from sepsis, pneumonia, influenza and Ebola.
Ann Transl Med. 2016 Nov;4(21):421. doi: 10.21037/atm.2016.11.03.
9
Treating Ebola patients: a 'bottom up' approach using generic statins and angiotensin receptor blockers.
Int J Infect Dis. 2015 Jul;36:80-4. doi: 10.1016/j.ijid.2015.04.019.
10
Treating the Host Response to Ebola Virus Disease with Generic Statins and Angiotensin Receptor Blockers.
mBio. 2015 Jun 23;6(3):e00716. doi: 10.1128/mBio.00716-15.
Zotero 插件